Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

COEP

Coeptis Therapeutics Holdings Inc

Dec 13 • 04:00PM ET

0.1779

Dollar change -0.0081
Percentage change -4.35	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN PFE MRNA BNTX JNJ VRTX AZN AMGN LLY

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.32	Insider Own	28.08%	Shs Outstand	39.97M	Perf Week	-2.52%
Market Cap	6.99M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	29.57M	Perf Month	-7.63%
Income	-11.62M	PEG	-	EPS next Q	-	Inst Own	8.76%	Short Float	0.92%	Perf Quarter	-1.39%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-16.31%	Short Ratio	0.69	Perf Half Y	-45.93%
Book/sh	0.17	P/B	1.03	EPS next Y	-	ROA	-127.52%	Short Interest	0.27M	Perf Year	-82.03%
Cash/sh	0.03	P/C	6.13	EPS next 5Y	-	ROE	-205.37%	52W Range	0.15 - 1.14	Perf YTD	-77.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-311.69%	ROI	-162.86%	52W High	-84.39%	Beta	-0.89
Dividend TTM	-	Quick Ratio	0.40	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	17.74%	ATR (14)	0.02
Dividend Ex-Date	-	Current Ratio	0.40	EPS Y/Y TTM	65.93%	Oper. Margin	-	RSI (14)	42.08	Volatility	11.14% 9.89%
Employees	7	Debt/Eq	0.26	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	80.70%	Payout	-	Rel Volume	1.07	Prev Close	0.19
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Aug 28	Avg Volume	394.20K	Price	0.18
SMA20	-8.42%	SMA50	-9.94%	SMA200	-33.01%	Trades		Volume	423,329	Change	-4.35%

Dec-12-24 08:00AM	Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies (PR Newswire)
Dec-03-24 08:15AM	Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries (PR Newswire) +17.51%
Nov-07-24 08:07AM	Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development (PR Newswire)
Oct-24-24 08:07AM	Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use (PR Newswire) -6.64%
Oct-15-24 08:07AM	Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy (PR Newswire)
07:07AM	Loading…
Sep-19-24 07:07AM	Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire) +5.47%
Sep-05-24 08:07AM	Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders (PR Newswire) -5.66%
Aug-16-24 08:52PM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024 (InvestorPlace) +5.15%
Jun-20-24 08:47AM	Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering (PR Newswire) -8.81%
May-30-24 08:47AM	Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting (PR Newswire)
May-13-24 09:53AM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.07%
May-08-24 08:47AM	Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 (PR Newswire)
May-02-24 08:47AM	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (PR Newswire) +8.77%
Apr-02-24 08:47AM	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award (PR Newswire) +6.68%
Feb-26-24 09:00AM	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PR Newswire) +9.89%
07:30AM	Loading…
Feb-07-24 07:30AM	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections (PR Newswire)
Jan-04-24 07:30AM	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 (PR Newswire) -10.71%
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) -7.02%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire) -5.00%
Dec-04-23 07:30AM	Coeptis Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Oct-31-23 09:01AM	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 (PR Newswire) -9.74%
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-24-23 08:30AM	Coeptis Therapeutics Announces $2 Million Private Placement (PR Newswire)
Oct-11-23 07:30AM	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology (PR Newswire)
Oct-09-23 09:15AM	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies (PR Newswire)
Oct-04-23 07:30AM	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (PR Newswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Sep-27-23 07:30AM	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa (PR Newswire) +10.31%
Sep-14-23 07:30AM	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection (PR Newswire)
Sep-11-23 07:30AM	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment (PR Newswire) -5.29%
01:00PM	Loading…
Aug-30-23 01:00PM	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer (PR Newswire)
Aug-17-23 07:30AM	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics (PR Newswire)
Aug-01-23 08:00AM	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic (PR Newswire)
Jun-16-23 04:00PM	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering (PR Newswire) -5.59%
Jun-14-23 09:28AM	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering (PR Newswire) +6.06%
Jun-09-23 07:00AM	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market (PR Newswire)
May-17-23 08:30AM	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer (PR Newswire)
May-10-23 03:00PM	Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications (PR Newswire)
Apr-18-23 07:30AM	Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics (PR Newswire) +9.16%
Mar-29-23 09:45AM	Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies (PR Newswire)
Mar-21-23 07:00AM	Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine (PR Newswire)
Feb-07-23 08:00AM	Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling (PR Newswire)
Jan-31-23 07:30AM	Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program (PR Newswire) +12.73%
Nov-22-22 07:00AM	Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program (PR Newswire) -6.17%
Nov-15-22 07:00AM	Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell (PR Newswire)
Nov-08-22 07:00AM	Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast (PR Newswire) -17.13%
Nov-02-22 07:00AM	Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments (PR Newswire) -8.81%
Sep-21-22 07:00AM	Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology (PR Newswire)
May-17-22 07:00AM	Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors (PR Newswire)
Apr-19-22 07:00AM	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement (PR Newswire)
Apr-13-22 04:05PM	Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod (GlobeNewswire)
07:00AM	Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma (PR Newswire)
Jan-20-22 08:00AM	Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development (PR Newswire)

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cogley Brian	Chief Financial Officer	Jan 10 '24	Buy	0.67	5,000	3,350	30,000	Jan 17 04:03 PM
DeSilva Tara	Director	Jan 12 '24	Buy	0.58	2,266	1,305	32,266	Jan 16 08:14 PM
Yerace Daniel Alexander	VP of Operations	Jan 05 '24	Buy	0.69	10,850	7,486	1,071,455	Jan 09 05:32 PM
Salkind Gene	Director	Jan 05 '24	Buy	0.69	11,600	8,004	284,056	Jan 09 05:31 PM
Mehalick David	CEO and President	Jan 08 '24	Buy	0.66	20,004	13,263	2,782,615	Jan 09 05:30 PM
Mehalick David	CEO and President	Jan 05 '24	Buy	0.69	5,050	3,484	2,762,611	Jan 09 05:30 PM
Cochran Christopher P.	Director	Jan 05 '24	Buy	0.77	7,000	5,390	37,000	Jan 09 05:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COEP

Coeptis Therapeutics Holdings Inc

Upgrade your FINVIZ experience